OBJECTIVE: To compare immediate changes in lung compliance following the administration of two commercially available natural surfactants. METHOD: We conducted a prospective, randomized study of 40 preterm infants with respiratory distress syndrome requiring surfactant. Infants received either Infasurf or Survanta. The primary outcome measure was the change in compliance assessed by bedside pulmonary monitoring. RESULTS: There were no significant changes in dynamic lung compliance within or between the two groups 1 hour after surfactant administration. However, infants given Survanta required more doses per patient (4 vs 2, p=0.05) and were more likely to require >2 doses (57 vs 26%, p=0.05). Infants requiring >1 dose of surfactant had a greater change in airway pressure and improved oxygenation just before the second dose when treated with Infasurf. CONCLUSIONS: We found no significant difference in acute changes in lung compliance. However, treatment with Infasurf seems to be more long lasting than Survanta.
RCT Entities:
OBJECTIVE: To compare immediate changes in lung compliance following the administration of two commercially available natural surfactants. METHOD: We conducted a prospective, randomized study of 40 preterm infants with respiratory distress syndrome requiring surfactant. Infants received either Infasurf or Survanta. The primary outcome measure was the change in compliance assessed by bedside pulmonary monitoring. RESULTS: There were no significant changes in dynamic lung compliance within or between the two groups 1 hour after surfactant administration. However, infants given Survanta required more doses per patient (4 vs 2, p=0.05) and were more likely to require >2 doses (57 vs 26%, p=0.05). Infants requiring >1 dose of surfactant had a greater change in airway pressure and improved oxygenation just before the second dose when treated with Infasurf. CONCLUSIONS: We found no significant difference in acute changes in lung compliance. However, treatment with Infasurf seems to be more long lasting than Survanta.
Authors: Neetu Singh; Henry L Halliday; Timothy P Stevens; Gautham Suresh; Roger Soll; Maria Ximena Rojas-Reyes Journal: Cochrane Database Syst Rev Date: 2015-12-21
Authors: Morgan D Lane; Sujata Kishnani; Obianuju Udemadu; Samuel Eshun Danquah; Robert M Treadway; Aaliyah Langman; Stephen Balevic; Wesley M Jackson; Matthew Laughon; Christoph P Hornik; Rachel G Greenberg; Reese H Clark; Kanecia O Zimmerman Journal: J Perinatol Date: 2021-07-20 Impact factor: 3.225